

INDEX

Contents	Page No.
List of Figures	x
List of Tables	xii
Abbreviations and Symbols	xiii
Preface	xvii
CHAPTER 1. INTRODUCTION	1
1.1 Neurodegenerative disorders	1
1.2 Alzheimer's disease	1
1.3 Pathogenesis of AD	3
1.3.1. Cholinergic hypothesis	3
1.3.2. A β hypothesis	5
1.3.3. The Tau (τ) protein theory	7
1.3.4. Oxidative stress hypothesis	8
1.3.5 Excitotoxic hypothesis	9
1.3.6 Apolipoprotein E (ApoE) hypothesis	9
1.3.7 CREB signaling pathways	9
1.3.8 The chronic inflammation hypothesis	10
1.4 Available neurotherapeutics for the treatment of AD	10
1.5 Description of a problem	11
1.6 Design hypothesis in the present study	12
CHAPTER 2. REVIEW OF LITERATURE	14
2.1 <i>Ferulic</i> acid as a multitargeted pharmacophore	14
2.2 1,3,4-Oxadiazoles as a multitargeted pharmacophore	18
2.3 Pyridyl ring as a multitargeted pharmacophore	22
2.4 Piperazine as a multitargeted pharmacophore	26
CHAPTER 3. RATIONALE, OBJECTIVES AND PLAN OF WORK	30
3.1. Rationale and objectives	30
3.1.1 Designing of Part-I (Series I and Series II) ligands	30
3.1.2 Designing of Part-II (Series III–IV) ligands	32
3.2. Plan of work	33
CHAPTER 4. EXPERIMENTAL	35
4.1 Synthesis	35
4.1.1 Chemicals and reagents	35
4.1.2 Series I: Ferulic acid tethered with benzylidenehydrazine and Series II: Ferulic acid tethered with 2-phenyl-1,3,4-oxadiazole.	35
4.1.2.1 General procedure for the synthesis of compound (3)	35
4.1.2.2 General procedure for the synthesis of target compounds, Series I (5a–o)	36
4.1.2.3 General procedure for the synthesis of target compounds, Series II (6a–o)	36

Contents	Page No.
4.1.3 Series III: Pyridyl piperazine analogs with substituted <i>N</i> '-benzylideneacetohydrazides (12a–o); and Series IV: Substituted 2-phenyl-1,3,4-oxadiazoles tethered with pyridyl piperazine (13a–o)	36
4.1.3.1 General procedure for the synthesis of compound (9)	37
4.1.3.2 General procedure for the synthesis of synthesis compound (10)	37
4.1.3.3 General procedure for the synthesis of target compounds (12a–o)	38
4.1.3.4 General procedure for the synthesis of target compounds (13a–o)	38
4.2 Characterization of the synthesized compounds	38
4.2.1 Melting point	38
4.2.2 TLC (R_f value)	38
4.2.3 Log P determination	39
4.2.4 FT-IR	39
4.2.5 ^1H NMR and ^{13}C NMR	39
4.2.6 Mass spectra	40
4.2.7 Determination of percentage purity by HPLC	40
4.3 Biological Evaluation	40
4.3.1 <i>In-vitro</i> studies	40
4.3.1.1 Cholinesterase inhibition by Ellman assay	40
4.3.1.2 Enzyme kinetics study	41
4.3.1.3 BACE-1 inhibition assay	41
4.3.1.4 Propidium iodide displacement assay	42
4.3.1.5 Parallel artificial membrane permeation assay (PAMPA)	43
4.3.1.6 $\text{A}\beta$ aggregation (self- and AChE-induced) inhibition by thioflavin T assay	43
4.3.1.7 AFM study	44
4.3.1.8 Neurotoxic liabilities against SH-SY5Y cell lines by MTT assay	45
4.3.2 <i>In-vivo</i> and <i>ex-vivo</i> studies	45
4.3.2.1 Animals	45
4.3.2.2 Acute oral toxicity study	46
4.3.2.3 Scopolamine-induced amnesia model: Y-maze test	46
4.3.2.4 <i>Ex-vivo</i> studies: AChE estimation and antioxidant activity	47
4.3.2.5 $\text{A}\beta$ -induced AD phenotypic model: Morris water maze test	48
4.3.3 Pharmacokinetic studies	50
4.4 Computational studies	51
4.4.1 <i>In silico</i> molecular docking study	51

Contents	Page No.
4.4.2 Molecular dynamics simulation study	51
CHAPTER 5. RESULTS AND DISCUSSION	52
5.1 PART-I: SERIES I	52
5.1.1 Chemistry	52
5.1.1.1 Synthesis of Series I: Ferulic acid analogues with substituted 3-(4-Hydroxy-3-methoxyphenyl)acrylohydrazide and Series II: Substituted 2-phenyl-1,3,4-oxadiazole tethered with Ferulic acid.	52
5.1.1.2 Characterization of the synthesized compounds (Series I)	53
5.1.2 Biological evaluation	65
5.1.2.1 <i>In-vitro</i> studies	65
5.1.2.2 <i>In-vivo</i> behavioral studies	73
5.1.2.3 <i>Ex-vivo</i> study	76
5.1.2.4 Pharmacokinetic study	77
5.1.3 <i>In silico</i> molecular docking study	78
5.2 PART-II: SERIES III–IV	81
5.2.1 Chemistry	81
5.2.1.1 Synthesis of Series III (12a–o): Pyridyl piperazine analogs with substituted N'-Benzylideneacetohydrazide; and Series IV (13a–o): Substituted 2-phenyl-1,3,4-oxadiazole tethered with Pyridyl piperazine	81
5.2.1.2 Characterization of the synthesized compounds (Series III and IV)	82
5.2.2 Biological evaluation	94
5.2.2.1 <i>In-vitro</i> biological evaluation	94
5.2.2.2 <i>In-vivo</i> behavioral studies	102
5.2.2.3 <i>Ex-vivo</i> study	105
5.2.2.4 Pharmacokinetic study	106
5.2.3 Computational studies	107
5.2.3.1 <i>In silico</i> molecular docking study	107
5.2.3.2 Molecular dynamics simulations study	108
CHAPTER 6. SUMMARY AND CONCLUSION	112
6.1. Scope and future directions	114
CHAPTER 7. REFERENCES	115
CHAPTER 8. APPENDIX	127
8.1. ¹ H and ¹³ C spectra of representative synthesized compounds	127
8.2. Mass spectra of representative synthesized compounds	137
8.3 HPLC chromatograms of representative synthesized compounds	142
LIST OF PUBLICATIONS	145